These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Ocrelizumab for multiple sclerosis. Lin M; Zhang J; Zhang Y; Luo J; Shi S Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174 [TBL] [Abstract][Full Text] [Related]
24. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA; Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593 [TBL] [Abstract][Full Text] [Related]
26. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Miller DH; Weber T; Grove R; Wardell C; Horrigan J; Graff O; Atkinson G; Dua P; Yousry T; Macmanus D; Montalban X Lancet Neurol; 2012 Feb; 11(2):131-9. PubMed ID: 22226929 [TBL] [Abstract][Full Text] [Related]
27. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L; N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954 [TBL] [Abstract][Full Text] [Related]
28. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Kappos L; Arnold DL; Bar-Or A; Camm J; Derfuss T; Kieseier BC; Sprenger T; Greenough K; Ni P; Harada T Lancet Neurol; 2016 Oct; 15(11):1148-59. PubMed ID: 27543447 [TBL] [Abstract][Full Text] [Related]
30. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336 [TBL] [Abstract][Full Text] [Related]
32. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611 [TBL] [Abstract][Full Text] [Related]